Denali Therapeutics Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Denali Therapeutics Inc. (DNLI) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$19.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $3.29M.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$22.39M.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $12.73M.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.89M, a 92.32% decline year-over-year.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $465.00K, a 85.68% decline from fiscal 2024.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $3.25M, a 22.66% increase from fiscal 2023.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $2.65M, a 75.75% decline from fiscal 2022.
- Denali Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $10.92M, a 130.73% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$19.11M 10-Q · filed 2026-08-06 | -$6.38M derived: sum of 3 quarters · filed 2026-08-06 | -$4.49M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$22.39M 10-Q · filed 2026-05-07 | -$9.67M derived: sum of 2 quarters · filed 2026-05-07 | -$7.78M derived: sum of 3 quarters · filed 2026-05-07 | -$12.24M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $12.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.62M derived: sum of 2 quarters · filed 2026-02-26 | $10.15M derived: sum of 3 quarters · filed 2026-08-06 | $465.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.58M derived: sum of 2 quarters · filed 2026-08-06 | -$12.26M 10-Q · filed 2025-11-06 | -$15.10M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$14.15M 10-Q · filed 2026-08-06 | -$16.99M derived: sum of 3 quarters · filed 2026-08-06 | $7.59M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$9.69M 10-Q · filed 2026-05-07 | -$6.48M 10-Q · filed 2025-05-06 | -$12.53M derived: sum of 2 quarters · filed 2026-05-07 | $12.06M derived: sum of 3 quarters · filed 2026-05-07 | -$8.76M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.74M derived: sum of 2 quarters · filed 2026-02-26 | $927.00K derived: sum of 3 quarters · filed 2026-02-26 | $3.25M 10-K · filed 2026-02-26 | $17.38M 10-K · filed 2025-02-27 | ||
| 2024-09-30 | $24.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.77M derived: sum of 2 quarters · filed 2025-11-06 | $6.09M 10-Q · filed 2025-11-06 | $20.40M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | -$20.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$18.50M 10-Q · filed 2025-08-11 | -$8.16M 10-Q · filed 2024-08-01 | -$4.18M derived: sum of 3 quarters · filed 2026-02-26 | -$3.45M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $2.32M 10-Q · filed 2025-05-06 | $16.63M derived: sum of 2 quarters · filed 2026-02-26 | $17.37M derived: sum of 3 quarters · filed 2026-02-26 | -$14.84M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.05M derived: sum of 2 quarters · filed 2026-02-26 | -$17.16M derived: sum of 3 quarters · filed 2026-02-26 | $2.65M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $734.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$31.48M derived: sum of 2 quarters · filed 2024-11-06 | -$11.66M 10-Q · filed 2024-11-06 | -$7.64M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | -$32.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$12.40M 10-Q · filed 2024-08-01 | -$8.37M derived: sum of 3 quarters · filed 2025-02-27 | $960.00K derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $19.81M 10-Q · filed 2024-05-07 | $23.84M derived: sum of 2 quarters · filed 2025-02-27 | $33.17M derived: sum of 3 quarters · filed 2025-02-27 | $39.03M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $13.36M derived: sum of 2 quarters · filed 2025-02-27 | $19.22M derived: sum of 3 quarters · filed 2025-02-27 | $10.92M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $9.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $15.20M derived: sum of 2 quarters · filed 2023-11-07 | $6.89M 10-Q · filed 2023-11-07 | $14.66M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-06-30 | $5.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.44M 10-Q · filed 2023-08-08 | $5.33M derived: sum of 3 quarters · filed 2024-02-28 | $11.82M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-03-31 | -$8.31M 10-Q · filed 2023-05-08 | -$538.00K derived: sum of 2 quarters · filed 2024-02-28 | $5.95M derived: sum of 3 quarters · filed 2024-02-28 | $7.23M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2021-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $14.26M derived: sum of 2 quarters · filed 2024-02-28 | $15.54M derived: sum of 3 quarters · filed 2024-02-28 | $4.73M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $6.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.77M derived: sum of 2 quarters · filed 2022-11-03 | -$3.04M 10-Q · filed 2022-11-03 | $14.19M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$9.53M 10-Q · filed 2022-08-08 | $7.70M derived: sum of 3 quarters · filed 2023-02-27 | $14.79M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | -$10.80M 10-Q · filed 2022-05-05 | $6.42M derived: sum of 2 quarters · filed 2023-02-27 | $13.52M derived: sum of 3 quarters · filed 2023-02-27 | $15.13M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $17.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $24.32M derived: sum of 2 quarters · filed 2023-02-27 | $25.93M derived: sum of 3 quarters · filed 2023-02-27 | $22.11M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $7.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.71M derived: sum of 2 quarters · filed 2021-11-04 | $4.88M 10-Q · filed 2021-11-04 | $3.50M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$2.21M 10-Q · filed 2021-08-04 | -$3.59M derived: sum of 3 quarters · filed 2022-02-28 | $1.17M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | -$3.83M 10-Q · filed 2021-05-05 | -$5.20M derived: sum of 2 quarters · filed 2022-02-28 | -$440.00K derived: sum of 3 quarters · filed 2022-02-28 | $2.27M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.39M derived: sum of 2 quarters · filed 2022-02-28 | $6.09M derived: sum of 3 quarters · filed 2022-02-28 | $1.50M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.47M derived: sum of 2 quarters · filed 2020-11-05 | $2.88M 10-Q · filed 2020-11-05 | $9.35M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$1.89M 10-Q · filed 2020-08-07 | $4.59M derived: sum of 3 quarters · filed 2021-02-26 | $8.63M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | -$4.59M 10-Q · filed 2020-05-07 | $1.88M derived: sum of 2 quarters · filed 2021-02-26 | $5.92M derived: sum of 3 quarters · filed 2021-02-26 | $7.78M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $6.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $10.52M derived: sum of 2 quarters · filed 2021-02-26 | $12.37M derived: sum of 3 quarters · filed 2021-02-26 | $9.11M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $5.90M derived: sum of 2 quarters · filed 2019-11-06 | $2.64M 10-Q · filed 2019-11-06 | $5.33M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$1.40M 10-Q · filed 2019-08-06 | $1.29M derived: sum of 3 quarters · filed 2020-02-27 | -$248.00K derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | -$3.26M 10-Q · filed 2019-05-08 | -$563.00K derived: sum of 2 quarters · filed 2020-02-27 | -$2.10M derived: sum of 3 quarters · filed 2020-02-27 | $1.26M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.16M derived: sum of 2 quarters · filed 2020-02-27 | $4.52M derived: sum of 3 quarters · filed 2020-02-27 | $3.58M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.83M derived: sum of 2 quarters · filed 2018-11-08 | $884.00K 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.42M 10-Q · filed 2018-08-09 | |||||
| 2017-03-31 | -$943.00K 10-Q · filed 2018-05-11 | ||||||
| 2016-12-31 | $5.36M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |